A study found a link between the likely presence of REM sleep behavior disorder (RBD) in people with Parkinson’s disease and greater frequency and severity of other nonmotor symptoms (NMS) that characterize the neurodegenerative disease. The researchers said the results link RBD to a Parkinson’s subtype called…
The U.S. Food and Drug Administration (FDA) has approved Onapgo (apomorphine hydrochloride) for the continuous treatment of motor fluctuations in adults with advanced Parkinson’s disease, making it the first subcutaneous, or under-the-skin, apomorphine infusion device approved for this indication. The application from Supernus Pharmaceuticals was the developer’s fourth…
Several promising strategies for developing therapeutics capable of crossing or bypassing the blood-brain barrier (BBB) offer potential for treating neurological conditions like Parkinson’s disease, but more work is needed to establish their benefits in clinical trials, a review study suggests. Strategies such as direct brain delivery, focused ultrasound, and…
Treatment with the anti-seizure medication levetiracetam led to a worsening of Parkinson’s disease symptoms for a woman in Saudi Arabia, according to a case report. The woman was given levetiracetam to prevent seizures after she fell and hit her head, but she soon after experienced deteriorating neurological and motor…
Blood levels of the fibronectin protein could be used as a predictor of disability in people with Parkinson’s disease, according to a recent study. Lower levels of the protein, referred to as plasma fibronectin (pFN), associated with a shorter time to reaching the start of a disability milestone like…
Scientists have developed a nanoparticle drug delivery system designed to enhance brain delivery of levodopa, the mainstay treatment for Parkinson’s disease, while also lowering a type of cellular damage called oxidative stress that’s implicated in the neurodegenerative condition. The system was able to improve motor function in a…
Data from a brief gait and posture assessment using wearable sensors — taking just a few minutes in the clinic — could help to accurately predict the risk of falls in the near future with Parkinson’s disease, a recent clinical study reported. Scientists at the University of Oxford in…
Treatment with investigational antibody therapy prasinezumab tended to slow the progression of motor symptoms in people with early-stage Parkinson’s disease in a Phase 2b trial, with particularly pronounced benefits among those also receiving levodopa. However, the difference between prasinezumab and a placebo in the overall study population…
The U.S. National Institutes of Health (NIH) launched a consortium to support clinical studies designed to better understand the link between the gut and brain in Parkinson’s disease. The Gut-Brain Communication in Parkinson’s Disease Consortium is motivated by the fact that there are compelling data indicating that the gastrointestinal…
Researchers in China have identified three genes — GPX2, CR1, and ZNF556 — with increased activity in people with Parkinson’s disease that could play a role in its development. If validated in future studies, these genes could ultimately serve as disease biomarkers to facilitate Parkinson’s diagnoses. “Our study identifies…
Get regular updates to your inbox.
